Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750555 · ClinicalTrials.gov registry record · Phase 2
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
A Phase 2 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00750555 is a Phase 2 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 4 participants.
The verdict
NCT00750555, a Phase 2 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
Interventions
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750555
The ClinicalTrials.gov registry entry for NCT00750555 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib is the first listed.
NCT00750555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750555 about?
NCT00750555 is a clinical study titled "Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer". Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
What is the current status of trial NCT00750555?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-09. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00750555?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00750555?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.